retatrutide triple agonist glp-1 gip glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

Collectively, these intertwined metabolic, inflammatory, and hemodynamic processes underpin the development and progression of DKD (Fig

doi:10.1111/ijd.70133

Retatrutide is generating a colossal amount of buzz in the research community, and for good reason

There is no evening decision fatigue, no "I will do it after dinner" that turns into "I forgot." Researchers who track their protocols using tools like the GLP-1 plotter consistently report better adherence with morning scheduling

Third, our approach: we'd rather under-treat and have you come back happy than over-treat and have you regret it

What happens after potential approval Assuming retatrutide eventually receives FDA approval, several practical questions arise for the research and clinical communities